Germany · Delayed Price · Currency is EUR Barinthus Biotherapeutics Statistics
Total Valuation
FRA:2AB has a market cap or net worth of EUR 26.86 million. The enterprise value is -26.99 million.
| Market Cap | 26.86M |
| Enterprise Value | -26.99M |
Important Dates
The next estimated earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.60% |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 35.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.37 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.42 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 1.02 |
Financial Position
The company has a current ratio of 8.04, with a Debt / Equity ratio of 0.14.
| Current Ratio | 8.04 |
| Quick Ratio | 7.33 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.37 |
| Interest Coverage | -1,097.24 |
Financial Efficiency
Return on equity (ROE) is -62.25% and return on invested capital (ROIC) is -25.56%.
| Return on Equity (ROE) | -62.25% |
| Return on Assets (ROA) | -23.02% |
| Return on Invested Capital (ROIC) | -25.56% |
| Return on Capital Employed (ROCE) | -55.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -615,913 |
| Employee Count | 105 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -98,015 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.01% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -26.01% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 0.90 |
| Relative Strength Index (RSI) | 43.50 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.22 |
Income Statement
| Revenue | n/a |
| Gross Profit | 8.96M |
| Operating Income | -46.76M |
| Pretax Income | -64.83M |
| Net Income | -64.67M |
| EBITDA | -44.06M |
| EBIT | -46.76M |
| Earnings Per Share (EPS) | -1.60 |
Balance Sheet
The company has 63.30 million in cash and 9.86 million in debt, giving a net cash position of 53.44 million.
| Cash & Cash Equivalents | 63.30M |
| Total Debt | 9.86M |
| Net Cash | 53.44M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 72.07M |
| Book Value Per Share | 1.76 |
| Working Capital | 64.76M |
Cash Flow
In the last 12 months, operating cash flow was -26.12 million and capital expenditures -268,475, giving a free cash flow of -26.39 million.
| Operating Cash Flow | -26.12M |
| Capital Expenditures | -268,475 |
| Free Cash Flow | -26.39M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:2AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.60% |
| Shareholder Yield | -3.60% |
| Earnings Yield | -240.76% |
| FCF Yield | -98.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:2AB has an Altman Z-Score of -3.52 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.52 |
| Piotroski F-Score | 1 |